Background: The schizophrenia whole disease model (WDM) developed by the applicants is the first health economic model which covers the entire schizophrenia care pathway in the UK, including prevention, diagnosis, and first-line and subsequent lines of treatment. However, due to a lack of RCT assessing different treatment sequences of antipsychotic medication, the effectiveness and safety data of subsequent lines of antipsychotic medications used in the WDM were obtained from network meta-analysis conducted for ‘general’ population with schizophrenia, rather than schizophrenia patients who have failed one or more different antipsychotic medications. To address this limitation, we plan to use the real-world evidence (RWE) included in the Clinical Record Interactive Search (CRIS) to derive the health and cost impacts of different treatment sequences of antipsychotic medications and update the WDM.
Novelty and Importance: To our knowledge, our study will be one of the first studies to use RWE to estimate the health and cost impacts of different antipsychotic sequence in people with schizophrenia. Our findings can help to improve the outcomes for people with schizophrenia by optimising the treatment sequence of antipsychotic medications and minimise the risk/severity of adverse effects.
Primary aim(s): To use the CRIS database to estimate the health and cost impacts of different treatment sequences of antipsychotic medication and use the data to update the schizophrenia WDM.
Training provided: (i) use the CRIS database; (2) use RWE to emulate a clinical trial; and (3) use/adapt the schizophrenia WDM.
Objectives / project plan
Year 1: Background reading, training, and apply access to CRIS.
Year 2: Use the data obtained from the CRIS database to estimate the health and cost impacts of different treatment sequence of antipsychotic medications.
Year 3: Use the derived data to update the schizophrenia WDM.
Year 4: Write up of the thesis and prepare papers for publication.